Blog Posts

Should NTCP models take the lead in radiation oncology treatment decisions? – ESTRO

ESTRO/LinkedIn

Apr 3, 2025, 09:43

Should NTCP models take the lead in radiation oncology treatment decisions? – ESTRO

ESTRO (European Society for Radiotherapy and Oncology) shared a post on LinkedIn:

“Debate Alert at ESTRO 2025! This house believes that NTCP models should be leading our clinical decision-making

Date: Saturday, May 3
Time: 15:15 – 16:30
Place: Schubert Room

Should Normal Tissue Complication Probability (NTCP) models take the lead in radiation oncology treatment decisions?

Join a dynamic Physics Track debate as leading experts go head-to-head:

For the motion: Markus Alber and Hans Langendijk

Against the motion: Tiziana Rancati and Ivan Vogelius

From opening statements to rebuttals and audience voting, this session promises lively discussion and critical insights into the role of predictive models in patient management.

Who will win? Be there and decide!”

Read further.

More posts featuring ESTRO.

cancer ESTRO ESTRO 2025 European SocieTy for Radiotherapy and Oncology Hans Langendijk Ivan Vogelius Markus Alber Normal Tissue Complication Probability NTCP OncoDaily Oncology radiation oncology Tiziana Rancati

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham